Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure
1. Novo Nordisk's CagriSema trial results disappointed investors and lowered share prices. 2. CagriSema achieved only 15.7% weight loss, below market expectations. 3. Investor sentiment is at an all-time low with some shorting the stock. 4. Upcoming REDEFINE-4 study in 2026 may clarify CagriSema's long-term efficacy. 5. Weight-loss drug market is projected to reach over $100 billion by 2030.